Abstract
With the increasing opportunities for medical management of von Hippel-Lindau (VHL)-related lesions, fundamental questions are arising regarding the possibilities of the FDA-Approved medication (Belzutifan) to delay the progression of other non-VHL-related tumors that are not requiring urgent surgical interventions. We present a follow-up report on a VHL patient, with a co-morbid history of pulmonary mucosa-Associated lymphoid tissue lymphoma, who was initially described in the clinical scientific literature ~10 years ago. This patient's case highlights some of the challenges for some VHL patients with comorbid non-VHL-related tumors and potential opportunities for targeted support.
Original language | English |
---|---|
Article number | rjae619 |
Number of pages | 2 |
Journal | Journal of Surgical Case Reports |
Volume | 2024 |
Issue number | 10 |
DOIs | |
Publication status | Published - 5 Oct 2024 |
Keywords
- lymphoma
- tumor
- von Hippel-Lindau
ASJC Scopus subject areas
- Surgery